The level of evidence is downgraded due to risk of bias (attrition bias, inadequate reporting) and imprecision (the confidence intervals for some outcomes are close to the null effect).
Adverse events were mainly mild gastrointestinal symptoms; serious events were rare. Weight regain was observed in a 26-week off-treatment follow-up period, reinforcing the concept that obesity is a chronic disease that requires continuous treatment. Long-term data on the use of liraglutide in children and adolescents is limited.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis | |||||
| «Kelly AS, Auerbach P, Barrientos-Perez M, et al. A...»1 Kelly et al. 2020 |
Randomized, double-blind, placebo-controlled phase 3 trial | 251 adolescents 12–17 years with obesity (BMI ≥95th percentile; adult-equivalent BMI
≥30), poor response to lifestyle therapy. Randomized: liraglutide n=125, placebo n=126. 32 sites in five countries: Belgium, Mexico, Russia, Sweden, USA. |
Liraglutide 3.0 mg s.c. once daily (or maximum tolerated dose) + lifestyle therapy. Comparison: Placebo s.c. once daily + lifestyle therapy. Duration 56 weeks. Follow-up 26 weeks off treatment. |
Primary: Change in BMI standard-deviation score at week 56. Key secondary: % with ≥5% and ≥10% BMI reduction; change in BMI (%), body weight (kg and %); safety. Off-treatment weight change to week 82. |
Moderate |
| «Fox CK, Barrientos-Pérez M, Bomberg EM ym. Liraglu...»2 Fox et al. 2025 |
Randomized, double-blind, placebo-controlled phase 3a trial | 82 children aged 6–11 years with obesity (BMI ≥95th percentile), Randomized: liraglutide n=56, placebo n=26. 23 sites in 9 countries; outpatient setting. |
Liraglutide 3.0 mg s.c. once daily (or maximum tolerated dose) + lifestyle intervention. Comparison: Placebo s.c. once daily + lifestyle intervention. Duration 56 weeks. Follow-up 26 weeks off treatment. |
Primary: % change in BMI at week 56. Secondary: % change in body weight; % with ≥5% BMI reduction; safety. | Moderate |
| Reference | Comments |
|---|---|
| «Kelly AS, Auerbach P, Barrientos-Perez M, et al. A...»1 | Factors influencing the risk of bias: attrition rate (20%), industry-funded study.
At week 56, treatment was completed by 101 participants (80.8%) in the liraglutide group and 100 participants (79.4%) in the placebo group. Among those who discontinued treatment, 12 of 24 in the liraglutide group and 5 of 26 in the placebo group underwent height and weight assessments at week 56. Baseline characteristics were similar in the two groups; randomization and blinding procedures were well-executed. Overall, the percentage of participants who reported adverse events during the treatment period was similar in the liraglutide group and the placebo group (88.8% and 84.9%, respectively). Most adverse events were mild or moderate. Gastrointestinal events including nausea, vomiting, and diarrhea were more common with liraglutide than with placebo. Serious adverse events were reported by 3 participants receiving liraglutide (three events) and 5 participants receiving placebo (six events). There were no apparent differences between treatment groups in growth or pubertal development. Industry-funded. |
| «Fox CK, Barrientos-Pérez M, Bomberg EM ym. Liraglu...»2 | Factors influencing the risk of bias: absolute changes in BMI were not reported; neither
were standard errors (or deviations) for most secondary outcomes. Small sample, industry-funded.
74 (90%) completed the main phase of the trial, and 66 (80%) received all the assigned doses of liraglutide or placebo, including 44 of 56 participants (79%) in the liraglutide group and 22 of 26 (85%) in the placebo group. Baseline characteristics were generally similar in the two groups. Industry-funded. Improvements were also observed in diastolic blood pressure and the glycated hemoglobin level in the liraglutide group; the data for systolic blood pressure showed a trend in the same direction, although the trial was not powered to detect small-size effects on systolic blood pressure. No notable changes in heart rates were reported. The most common adverse events reported in the liraglutide group were gastrointestinal, including nausea, vomiting, and diarrhea. Three cases of vomiting in the liraglutide group were considered by investigators to be serious (each required emergency care); however, none of the events required hospitalization. Liraglutide had no apparent adverse effects on growth and development when evaluated after 56 weeks of treatment. |
Results
| Reference | Number of patients (I/C) | Follow-up time | Change from baseline, I | Change from baseline, C | Difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low. Evidence is downgraded due to risk of bias (attrition, inadequate
reporting) and imprecision (the confidence intervals are close to the null effect). I= intervention; C=comparison; CI=confidence interval |
|||||
| «Kelly AS, Auerbach P, Barrientos-Perez M, et al. A...»1 Kelly et al. |
125/126 | 56 weeks | -0.23+/-0.05 |
0.00 +/-0.05 | -0.22 (-0.37 to -0.08) |
| 82 weeks (26 weeks off treatment) | Change from week 56 +0.22 |
Change from week 56 +0.07 |
+0.15 (0.07 to 0.23) | ||
| «Fox CK, Barrientos-Pérez M, Bomberg EM ym. Liraglu...»2 Fox et al. |
56/26 | 56 weeks | -0.7 | -0.3 | -0.4 (-0.6 to -0.2) |
| Reference | Number of patients (I/C) | Follow-up time | Change from baseline, I | Change from baseline, C | Difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: moderate. Evidence is downgraded due to risk of bias (attrition,
inadequate reporting) I= intervention; C=comparison; CI=confidence interval |
|||||
| «Kelly AS, Auerbach P, Barrientos-Perez M, et al. A...»1 Kelly et al. |
125/126 | 56 weeks |
Absolute +/-SE -1.39 +/- 0.31 kg/m2 Relative -4.29 % |
Absolute +/- SE +0.19 +/- 0.33 kg/m2 Relative +0.35 % |
-1.58 (-2.47 to -0.69) -4.64 % (-7.14 to -2.14%) |
| 82 weeks (26 weeks off treatment) | Absolute +/- SE -0.2 +/- 3.5 kg/m2 |
Absolute +/- SE +0.8 +/- 4.0 kg/m2 |
Not reported | ||
| «Fox CK, Barrientos-Pérez M, Bomberg EM ym. Liraglu...»2 Fox et al. |
56/26 | 56 weeks | Absolute change not reported Relative -5.8% |
Absolute change not reported Relative +1.6% |
-7.4 % (-11.6 to -3.2%) |
| 82 weeks (26 weeks off treatment) | Absolute change not reported Relative -0.8% |
Absolute change not reported Relative +6.7% |
Not reported | ||
| Reference | Number of patients (I/C) | Follow-up time | Change in kg +/- SE, I | Change in kg+/- SE, C | Difference (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: moderate. Evidence is downgraded due to risk of bias (attrition,
inadequate reporting). I= intervention; C=comparison; CI=confidence interval |
|||||
| «Kelly AS, Auerbach P, Barrientos-Perez M, et al. A...»1 Kelly et al. |
125/126 | 56 weeks | -2.26 +/- 0.94 kg | +2.25 +/- 0.98 kg | -4.50 (-7.17 to -1.84) kg |
| 82 weeks (26 weeks off-treatment) | +1.7 +/-10.1 kg | +4.4 +/-11.7 kg | Not reported | ||
| «Fox CK, Barrientos-Pérez M, Bomberg EM ym. Liraglu...»2 Fox et al. |
56/26 | 56 weeks | +1.1 kg | +7.1 kg | -6.0 kg (-9.3 to -2.7) |